ClinicalTrials.gov record
Terminated Phase 1Phase 2 Interventional

Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors

ClinicalTrials.gov ID: NCT03684785

Public ClinicalTrials.gov record NCT03684785. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 14, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors: A Phase 1b/2 Study of Cavrotolimod Combined With Pembrolizumab or Cemiplimab

Study identification

NCT ID
NCT03684785
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Exicure, Inc.
Industry
Enrollment
57 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 12, 2018
Primary completion
Mar 29, 2022
Completion
Mar 29, 2022
Last update posted
Apr 6, 2022

2018 – 2022

United States locations

U.S. sites
26
U.S. states
19
U.S. cities
24
Facility City State ZIP Site status
University of Arizona Cancer Center Tucson Arizona 85719
University of California Irvine Orange California 92868
UCSF Helen Diller Family Comprehensive Cancer Center San Francisco California 94185
John Wayne Cancer Institute / Providence St. John's Health Center Santa Monica California 90401
University of Colorado Cancer Center Aurora Colorado 80045
Western States Cancer Center Englewood Colorado 80113
Sylvester Comprehensive Cancer Center Miami Florida 33136
Northwestern University Feinberg School of Medicine Chicago Illinois 60611
Holden Comprehensive Cancer Center Iowa City Iowa 52242
Norton Cancer Center Louisville Kentucky 40241
Dana Farber Cancer Institute Boston Massachusetts 02215
Washington University St. Louis St Louis Missouri 63110
Dartmouth-Hitchcock Medical Center Lebanon New Hampshire 03756
Valley - Mount Sinai Comprehensive Cancer Center Paramus New Jersey 07652
Perlmutter Cancer Center New York New York 10016
Memorial Sloan Kettering Cancer Center New York New York 10065
Duke Cancer Institute Durham North Carolina 27710
University of Cincinnati Cincinnati Ohio 45267
Ohio State University Comprehensive Cancer Center Columbus Ohio 43210
Oregon Health and Science University Portland Oregon 97239
University of Pittsburgh Medical Center / Hillman Cancer Center Pittsburgh Pennsylvania 15232
Sammons Cancer Center Dallas Texas 75246
Baylor College of Medicine Houston Texas 77030
MD Anderson Cancer Center Houston Texas 77030
University of Washington- Seattle Cancer Care Alliance Seattle Washington 98109
West Virginia Cancer Institute Morgantown West Virginia 26506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03684785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 6, 2022 · Synced May 14, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03684785 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →